Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal Carcinoma

Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18-75
SponsorFudan University

About this trial

This study was a single-arm, open-label, "3 + 3" dose-escalation Exploratory research. The patients were divided into two groups: EBV TCR-T-cell Group and EBV CAR-T-cell group. The EBV CAR-T-treated group received three progressively increasing dose levels (3.0 × 106 cells/kg, 9.0 × 106 cells/kg, 1.5 × 107 cells/kg) of EBV CAR-T-cell therapy; The EBV TCR-T-cell group received three progressively increasing doses (5.0 × 106 cells/kg, 1.5 × 107 cells/kg, 3.0 × 107 cells/kg) of EBV TCR-T-cell therapy.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Voluntary written informed consent;

Age ≥18 years old, ≤75 years old, male and female;

Expected survival ≥3 months;

The Eastern Cooperative Oncology Group (ECOG) physical fitness score was 0-2;

Disqualifiers

Active central nervous system metastases (except those that are stable after treatment);

HIV positive, HBsAg positive and HBV DNA copy number positive (quantitative detection ≥1000 CPS/ml) , HCV antibody positive and HCV RNA positive;

Patients with mental or psychological disorders who can not cooperate with the treatment and evaluation of the curative effect;

Subjects with severe autoimmune disease and long-term use of immunosuppressants;

Trial design

Design model

Parallel

Treatments tested in this trial

  • PK Blood Collection

    Behavioral

    All subjects were subjected to PK blood sampling as prescribed by the protocol.

  • CAR

    Drug

    Target A positive subjects will receive CAR-T cell therapy.

  • TCR

    Drug

    Target A negative, Target B positive and Target C positive subjects will receive TCR-T cell therapy.

Treatment groups

24 Participants
are divided into 2 treatment groups
Group A: CAR-TExperimental treatment 2 interventions
Group B: TCR-TExperimental treatment 2 interventions

Trial outcomes

Primary outcomes

1

Dose Limiting Toxicities

Analysis based on clinical trial data of subjects

Time frame
one year
2

MTD or the best effective dose

Analysis based on clinical trial data of subjects

Time frame
one year
3

Incidence of AE、SAE、AESI

Analysis based on clinical trial data of subjects

Time frame
one year

Secondary outcomes

1

PK parameter:Cmax

Analysis based on clinical trial data of subjects

Time frame
one year
2

PK parameter:Tmax

Analysis based on clinical trial data of subjects

Time frame
one year
3

ORR

Analysis based on clinical trial data of subjects

Time frame
one year
4

DCR

Analysis based on clinical trial data of subjects

Time frame
one year

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.